Marshall Wace North America’s Novartis NVS Stock Holding History

Marshall Wace North America’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-31,006	Closed	-$2.69M	–	1497
2019 Q3	$2.69M	Sell	31,006 -51,145	-62%	-$4.59M	0.02%	481
2019 Q2	$7.5M	Buy	82,151 +75,231	+1,087%	+$6.37M	0.05%	282
2019 Q1	$596K	Sell	6,920 -550,784	-99%	-$44.2M	﹤0.01%	762
2018 Q4	$42.9M	Buy	557,704 +82,619	+17%	+$6.43M	0.42%	68
2018 Q3	$36.7M	Sell	475,085 -432,381	-48%	-$32M	0.25%	100
2018 Q2	$61.4M	Sell	907,466 -950,195	-51%	-$65.6M	0.35%	66
2018 Q1	$135M	Buy	1,857,661 +266,161	+17%	+$20.3M	0.67%	25
2017 Q4	$120M	Buy	1,591,500 +623,156	+64%	+$47M	0.66%	24
2017 Q3	$74.6M	Sell	968,344 -108,536	-10%	-$8.2M	0.47%	34
2017 Q2	$80.1M	Buy	1,076,880 +302,212	+39%	+$21.4M	0.59%	29
2017 Q1	$51.4M	Buy	+774,668	New	+$51.6M	0.41%	67

Other funds holding NVS

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $14.7B AUM 12.5% 1-Year Est. Return

Marshall Wace North America's NVS Position: Q4 2019 in Review

Marshall Wace North America sold out of Novartis (NVS) in Q4 2019, closing a stake of 31,006 shares — an estimated $2.69M sold.

Marshall Wace North America first reported a position in NVS in Q1 2017 and held it in 11 quarters. The position peaked at $135M in Q1 2018. 1,173 funds tracked by Wall St. Rank hold NVS as of Q4 2019.

Marshall Wace North America reported no remaining Novartis position as of Q4 2019 after selling out during the quarter.
Marshall Wace North America sold 31,006 Novartis shares in Q4 2019, an estimated $2.69M.
Marshall Wace North America first reported a position in Novartis in Q1 2017 and held it in 11 quarters.
Marshall Wace North America's Novartis position peaked at $135M in Q1 2018.
1,173 funds tracked by Wall St. Rank held Novartis as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.